Ovagen
Also known as: Glu-Asp-Leu, EDL
Key Facts: Ovagen
- Category
- Bioregulators
- FDA Status
- Not FDA Approved
- Clinical Status
- Preclinical research, approved in Russia as supplement
- Administration
- Oral capsules or sublingual
- Typical Dose
- 10-20 mg daily
- Frequency
- Once or twice daily
- Duration
- 10-30 day cycles
Mechanism of Action
The general bioregulator hypothesis holds that di- and tripeptides like EDL are small enough to be carried into cells through peptide transporters (the PEPT1 and PEPT2 systems that normally absorb dietary peptide fragments), after which they are proposed to influence transcription in a tissue-selective manner. For Ovagen the claimed targets are hepatocytes (liver cells) and gastrointestinal epithelium. This is a proposed model extrapolated from the broader Khavinson peptide research, not a mechanism that has been directly and independently demonstrated for Ovagen itself. As with the other bioregulators, the leap from "short peptide enters cell" to "specifically reprograms organ-level gene expression" is not supported by mainstream molecular evidence.
Research Summary
Ovagen is one of the more obscure entries in this category and the verifiable research is sparse. The broader peptide-bioregulator literature, much of it from a single Russian institute, reports gene-expression and chromatin effects for canonical members like Epitalon (AEDG) and Vilon (KE), and Ovagen is described as belonging to that same general class. But specific, independently reproduced studies on EDL itself are hard to find, and the claims that it reduces liver fibrosis or protects gut mucosa trace back to product marketing rather than controlled experiments. There are no registered human clinical trials of Ovagen and no high-quality evidence that it treats any liver or digestive condition in people. Anyone evaluating it should understand it as an unproven research compound whose marketed benefits far outrun the published science.
Dosing Information
Note: Animal study doses may not translate directly to humans.
Typical Dosingⓘ
Community experience
10-20 mg daily
10-20 mg daily
Once or twice daily
Khavinson bioregulator for liver/GI. Part of the peptide bioregulator system.
Research Dosingⓘ
Scientific studies
Doses from bioregulator supplement protocols
Doses from Studies
10-20 mg daily
Duration
10-30 day cycles
Administration
Oral capsules or sublingual
Timing & Administration
Best Time to Take
Morning on empty stomach
Once or twice daily
Food Recommendation
Take on empty stomach
Why This Timing?
Peptide bioregulators typically taken fasted for optimal absorption
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Generally well-tolerated
- ●Limited safety data outside Russia
- ●Not FDA approved
References
- https://www.mdpi.com/1420-3049/26/22/7053
- https://www.mdpi.com/1420-3049/25/3/609
- https://pubmed.ncbi.nlm.nih.gov/37042594/
- https://khavinson.info/publications
Research This Peptide Further
Frequently Asked Questions
What does Ovagen do?
Ovagen is a synthetic ultra-short peptide, marketed as the tripeptide Glu-Asp-Leu (EDL), and grouped with the Khavinson-style "peptide bioregulators" promoted for liver and gastrointestinal support. Like its cousins in that family, it is claimed to act at the gene-expression level in a tissue-specific way. The honest picture: there is very little verifiable scientific data on Ovagen specifically, no clinical trials, and most of what is written about it comes from vendors rather than peer-reviewed research.
How does Ovagen work?
The general bioregulator hypothesis holds that di- and tripeptides like EDL are small enough to be carried into cells through peptide transporters (the PEPT1 and PEPT2 systems that normally absorb dietary peptide fragments), after which they are proposed to influence transcription in a tissue-selective manner. For Ovagen the claimed targets are hepatocytes (liver cells) and gastrointestinal epithelium. This is a proposed model extrapolated from the broader Khavinson peptide research, not a mechanism that has been directly and independently demonstrated for Ovagen itself. As with the other bioregulators, the leap from "short peptide enters cell" to "specifically reprograms organ-level gene expression" is not supported by mainstream molecular evidence.
Is Ovagen FDA approved?
No, Ovagen is not currently FDA approved. Current status: Preclinical research, approved in Russia as supplement
What are the side effects of Ovagen?
Reported side effects include: Generally well-tolerated, Limited safety data outside Russia, Not FDA approved. Individual responses vary based on dosage, duration, and personal health factors.
What is the typical dose of Ovagen?
Community-reported common dose: 10-20 mg daily (Once or twice daily). Range: 10-20 mg daily. Administration: Oral capsules or sublingual. Community-reported doses. Not medical advice. Consult healthcare provider.
Related Peptides
Peptides commonly compared with Ovagen or used in similar applications.
Livagen
PreclinicalLivagen is a synthetic tetrapeptide (Lys-Glu-Asp-Ala, or KEDA) from the family of short "peptide bioregulators" developed by Vladimir Khavinson's group in St. Petersburg, marketed in connection with liver and immune function. The proposed appeal is epigenetic: it has been reported to loosen tightly packed chromatin in aged cells, supposedly switching age-silenced genes back on. Evidence is limited to small laboratory and cell studies, mostly from one research group, with no clinical trials, so claims should be read with heavy skepticism.
BioregulatorsCortagen
PreclinicalCortagen is a synthetic tetrapeptide (Ala-Glu-Asp-Pro, AEDP) from Vladimir Khavinson's Russian peptide bioregulator program, designed as the defined-sequence stand-in for Cortexin, an older cattle brain cortex extract used in Russian neurology. It is studied mostly for nerve repair, brain function and aging, and it is not approved by the FDA or EMA. Real evidence is limited to animal experiments and Russian-institute work, with no Western randomized human trials.
BioregulatorsVesugen
PreclinicalVesugen is a synthetic tripeptide (Lys-Glu-Asp, or KED) from the Khavinson family of short peptide bioregulators, studied for vascular and neuroprotective effects. It is a research compound, not an approved drug, with no registered human clinical trials.
BioregulatorsChonluten
PreclinicalChonluten is a synthetic tripeptide (Glu-Asp-Gly, EDG) from the Khavinson bioregulator family, pitched as the lung and bronchial peptide, derived conceptually from the same program that produced Epitalon and Cortagen. It is researched for respiratory tissue and age-related lung decline, and it has no FDA or EMA approval. The evidence is essentially all preclinical or uncontrolled Russian clinical observation, with no randomized human trials.
BioregulatorsCrystagen
PreclinicalCrystagen is a synthetic tripeptide (Glu-Asp-Pro, or EDP) from the Khavinson family of short peptide bioregulators, studied as an immune and thymic regulator. It is a research compound, not an approved drug, with no registered human clinical trials. Note: many vendor pages list the wrong sequence; the correct one is Glu-Asp-Pro (EDP).
BioregulatorsProstamax
PreclinicalProstamax is a synthetic Khavinson tetrapeptide (Lys-Glu-Asp-Pro, KEDP) marketed as a prostate bioregulator, conceived as the defined-sequence successor to the older bovine prostate extracts Prostatilen and Vitaprost. It is studied for prostate inflammation and age-related prostate changes, and it has no FDA or EMA approval. Most of the actual clinical prostate evidence belongs to the parent extract, not to the synthetic KEDP peptide itself.
BioregulatorsWant updates on Ovagen research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.